eliquis apixaban eliquis apixaban eliquis apixaban logo

This information is intended for healthcare professionals based in the UK.

If you are not a healthcare professional in the UK, please click here.

For Prescribing and Adverse Event reporting information, click here.

desk-img mob-img

Eliquis (apixaban) HALF-LIFE & Excretion

ELIQUIS has low renal excretion1

desk-img mob-img
  • ELIQUIS has multiple routes of elimination1
  • Of the administered ELIQUIS dose in humans, approximately 25% was recovered as metabolites, with the majority recovered in faeces1
  • Additional contributions from biliary and direct intestinal excretion were observed in clinical and non-clinical studies, respectively1
  • Renal excretion of ELIQUIS accounts for approximately 27% of total clearance1

ELIQUIS has a half-life of approximately 12 hours1

With a half-life of 12 hours, ELIQUIS twice-daily dosing gives your patients stable coverage throughout the day.1,2


ELIQUIS is available for your patients with NVAF1

ELIQUIS is available for your patients with DVT / PE1

View information to assist your daily practice, including adverse reactions, contraindications and interactions

Purple information icon ELIQUIS (apixaban) SmPC

Please click here to access the ELIQUIS SmPC.

Purple information icon ELIQUIS (apixaban) Patient Information Leaflet

Please click here to access the ELIQUIS Patient Information Leaflet.

DVT = Deep Vein Thrombosis   
NVAF = Non-Valvular AF   
PE = Pulmonary Embolism


  1. ELIQUIS® (apixaban) Summary of Product Characteristics.
  2. Lassen et al. J Thromb Haemost 2007; 5: 2368–2375.